Rather & Kittrell’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rather & Kittrell’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7	Closed	–	–	88
2021 Q4	$0	Buy	+7	New	+$578	﹤0.01%	315

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Rather & Kittrell's BMRN Position: Q1 2022 in Review

Rather & Kittrell sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 7 shares.

Rather & Kittrell first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Rather & Kittrell reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 7 BioMarin Pharmaceuticals shares in Q1 2022.
Rather & Kittrell first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's BioMarin Pharmaceuticals position peaked at $0 in Q4 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.